Monday, 20 Jan 2020

Biologic/Novel Rx

Datesort ascending Type Title Save
02 Jan 2020 News Best of 2019 - Is Methotrexate Necessary with Tofacitinib?
01 Jan 2020 Social Do biologics work in relapsing polychondritis? French cohort of 41 pts use 105 biologics (TNFi=60; TCZ 17; anakinra 15; RTX 7; ABA6). While 63% resp in 1st 6 mos (on pred!), a complete response rate was 19%. Steroid sparing variable, high infx rates.
31 Dec 2019 News Best of 2019 - Ups and Downs with Abatacept
30 Dec 2019 News Best of 2019 - Are Non-TNF Biologics Superior to TNF inhibitors?
26 Dec 2019 News Best of 2019 - New EMA Warnings for Tofacitinib in Patients at Risk for Clots
25 Dec 2019 News Best of 2019 - Upadacitinib (RINVOQ) FDA Approved for Rheumatoid Arthritis
23 Dec 2019 News Gilead Submits Filgotinib NDA to the FDA
16 Dec 2019 Social FDA has approved Xeljanz XR (tofacitinib) extended-release 11 mg and 22 mg tablets for the once-daily use in moderately to severely active ulcerative colitis (UC), after an inadequate response or intolerance to TNF blockers.
11 Dec 2019 Social Biosimilar Tote-Board in Rheumatology: 4 Infliximab biosimilars - Inflectra, Renflexis, Ifixi, Avsola 5 Adalimumab biosimilars - Amjevita, Cyltezo, Hyrimoz, Hadlima, Abrilada 2 Etanercept biosimilars - Erelzi, Enticovo 2 Rituximab biosimilars - Truxima, Ruxience
11 Dec 2019 Social FDA has approved Amgen’s infliximab biosimilar, Avsola (infliximab-axxq),for use in Crohns, UC, RA, AS, PsA and psoriasis, based on a 566 pt trial in RA. This is the 4th infliximab biosimilar in the US, joining Inflectra, Renflexis, and Ixifi.
10 Dec 2019 News Variations in First Biologic Use in Rheumatoid Arthritis
10 Dec 2019 Social BEST JOURNAL TITLE OF THE WK - "The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis."
28 Nov 2019 Social RT @RheumNow: Abstract L06 shows the efficacy of Emapalumab, an IFN-γ mAb, when given to 9 systemic JIA pts who developed macrophage activ…
26 Nov 2019 Social The EMA has approved a subcutaneous version of Celltrion infliximab biosimilar, CT-P13 - now called Remsima SC; based on the phase I/III study showing equivalence between SC and IV forms of CT-P13 SC in active rheumatoid arthritis (RA).
26 Nov 2019 News BMS and Celgene Merge as Amgen Buys Otezla
21 Nov 2019 Social FINCH3: FILGOTINIB studied in this cohort naive to MTX; interesting that safety data looks good! Maybe too early to tell. Abst# 927
20 Nov 2019 News ACR 2019 – Best of the Plenary Sessions
20 Nov 2019 ACR Video Subcutaneous Biosimilar: Dr. Jonathan Kay
18 Nov 2019 ACR Video Emapalumab Treatment in Macrophage Activation Syndrome: Dr. Fabrizio De Benedetti
18 Nov 2019 ACR Video Biosimilars: Dr. Arthur Kavanaugh